Advaxis shares closed Friday at 47 cents, right around where it hit a few months after the biotech reported that the FDA had placed its then lead drug — axalimogene filolisbac — on clinical hold due to what it said were CMC issues.
Similarly How can I buy advaxis stock? How to buy shares in Advaxis
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. …
- Research the stock. …
- Purchase now or later. …
- Check in on your investment.
What will happen to advaxis stock after merger? Following the closing, Advaxis will be renamed Biosight Therapeutics and is expected to trade on the Nasdaq Capital Market under the ticker symbol “BSTX”. The merger agreement may be terminated under certain customary and limited circumstances at any time prior to the closing.
Additionally, Is advaxis a penny stock?
Penny Stocks: Advaxis (ADXS)
Advaxis is small-cap clinical-stage biotech company that develops therapeutics for its cutting-edge attenuated delivery products. It has a promising product pipeline, which includes three therapeutic programs in various trial stages.
Does Adxs stock go up?
Stock Price Forecast
The 1 analysts offering 12-month price forecasts for Advaxis Inc have a median target of 2.25, with a high estimate of 2.25 and a low estimate of 2.25. The median estimate represents a +2,127.72% increase from the last price of 0.10.
Who is Adxs merging with? With the latest results, the company said it planned to “continue to explore additional options to maximize stockholder value.” Advaxis (ADXS) shares have gained ~12.6% in the pre-market. Read more on the merger deal between Advaxis (ADXS) and Biosight, as announced by the companies in July.
